SLGL — Sol-Gel Technologies Ltd.

Is SLGL overbought or oversold? Here is the current MarketMoodz read.

Healthcare · Biotechnology

Strong Oversold As of November 17, 2026

Sol-Gel Technologies Ltd. (SLGL) currently reads Strong Oversold on the MarketMoodz overbought/oversold meter, as of November 17, 2026. The Healthcare name (Biotechnology) last closed at $54.96. The rating moved from Oversold to Strong Oversold on November 14, 2026.

See all oversold Healthcare stocks →

AI analysis

Sol-Gel Technologies Ltd. (SLGL) is a small-cap specialty materials/medtech name with potential upside from commercialization milestones and distribution expansion but limited transparency on recent financials and filings increases uncertainty. The company’s niche product set can provide recurring revenue if adoption and reimbursement progress, yet near-term performance is likely to be driven by idiosyncratic news. Market conditions are currently cautious and favor defensive large-caps, which may suppress short-term momentum for microcap healthcare names. Key scenarios include meaningful upside if partnerships or positive clinical/commercial updates arrive, or outsize downside if capital needs, regulatory setbacks, or competitive pressures materialize.

Key factors

  • Sol-Gel Technologies Ltd. (SLGL) operates in niche dental/medical materials where recurring consumables and specialty products can generate steady revenue if commercialization scales.
  • Small-cap market positioning with limited liquidity makes the stock sensitive to discrete news, distribution deals, or clinical updates.
  • Visibility into recent financials and filings is limited (no EDGAR comparison provided), constraining near-term fundamentals assessment.
  • Potential near-term catalysts include product commercialization milestones, new distribution or OEM agreements, clinical data readouts, or partnership announcements.
  • Current market tone is cautious and tilted to defensive sectors, which may reduce short-term investor appetite for microcap healthcare names.

Risks

  • Uncertain cash runway and the potential need for dilutive financing or capital raises that could materially impact equity value.
  • Regulatory and reimbursement risk for medical/dental products; approvals or payer coverage setbacks would hamper adoption and revenue.
  • Intense competition from larger, better-funded dental and medtech companies that can leverage scale, distribution, and R&D budgets.
  • Low daily trading volume and market microstructure risks that can amplify price moves and create liquidity-driven volatility.
  • Limited public disclosure / lack of recent EDGAR analysis and no social sentiment data, creating information asymmetry for investors.
  • Macro risk: risk-off flows and higher-for-longer rate expectations reduce risk appetite for small, growth-oriented healthcare names.

See today's live rating, score and targets

Members see the live hourly rating for SLGL — the numeric AI score plus targets and entry zones — while this public page updates nightly.

Start the 14-day trial

This page is for informational purposes only and is not investment, financial, tax, or legal advice. Ratings and research outputs can be wrong, incomplete, or stale. Past performance does not guarantee future results. Always do your own research and consider consulting a qualified professional.